Results 11 to 20 of about 204,961 (215)

Impact of Gut Microbiota and Microbiota-Related Metabolites on Hyperlipidemia

Frontiers in Cellular and Infection Microbiology, 2021
Hyperlipidemia, defined as the presence of excess fat or lipids in the blood, has been considered as a high-risk factor and key indicator of many metabolic diseases.
Xiaokang Jia, Wen Xu, Xiaoyan Li
exaly   +4 more sources

Alterations of Gut Microbiota and Blood Lipidome in Gestational Diabetes Mellitus With Hyperlipidemia

Frontiers in Physiology, 2019
Clinical gestational diabetes mellitus (GDM) is frequently associated with hyperlipidemia comorbidity. Altered human gut microbiome has been linked to GDM and hyperlipidemia, respectively but not the comorbid condition. We hypothesize that the occurrence
He Liu, Li-long Pan, Qin Yang
exaly   +4 more sources

A cross-sectional study exploring the relationship between the dietary inflammatory index and hyperlipidemia based on the National Health and Nutrition Examination Survey (2005–2018)

Lipids in Health and Disease, 2023
Background Hyperlipidemia is closely associated with dietary patterns and inflammation. However, the relationship between hyperlipidemia and the inflammatory potential of diets remains unexplored.
Yu Han, Xijuan Jiang, Yabin Qin, Yile Zhao, Guying Zhang, Chao Liu   +5 more
doaj   +2 more sources

Linderae Radix Ethanol Extract Alleviates Diet-Induced Hyperlipidemia by Regulating Bile Acid Metabolism Through gut Microbiota

Frontiers in Pharmacology, 2021
Hyperlipidemia is a common metabolic disorder and regarded as one of the main risk factors for cardiovascular disease. The gut microbiota has been identified as a potential contributor to hyperlipidemia as it can greatly regulate bile acid metabolism ...
Tao Jiang, Guangji Zhang, Zhaohuan Lou
exaly   +2 more sources

Association between Systemic Immunity-Inflammation Index and Hyperlipidemia: A Population-Based Study from the NHANES (2015–2020)

Nutrients, 2023
The systemic immunity-inflammation index (SII) is a novel inflammatory marker, and aberrant blood lipid levels are linked to inflammation. This study aimed to look at the probable link between SII and hyperlipidemia.
Nayili Mahemuti, X. Jing, N. Zhang, Chuanlan Liu, Changping Li, Z. Cui, Yuanyuan Liu, Jiageng Chen   +7 more
semanticscholar   +1 more source

Postprandial Hyperlipidemia: Its Pathophysiology, Diagnosis, Atherogenesis, and Treatments

International Journal of Molecular Sciences, 2023
Postprandial hyperlipidemia showing postprandial increases in serum triglyceride (TG) is associated with the development of atherosclerotic cardiovascular disease (ASCVD).
H. Yanai, H. Adachi, M. Hakoshima, H. Katsuyama   +3 more
semanticscholar   +1 more source

Hyperlipidemia in tendon injury: chronicles of low-density lipoproteins

Cell and Tissue Research, 2023
Hyperlipidemia impacts millions of people globally and has been the major risk factor for developing atherosclerosis and cardiovascular disease. Interestingly, hyperlipidemic subjects exhibit increased incidence of rotator cuff tendon injury (RCTI) and ...
William H. Fang, Victor Bonavida, D. Agrawal, Finosh G. Thankam   +3 more
semanticscholar   +1 more source

Distribution of lipid levels and prevalence of hyperlipidemia: data from the NHANES 2007–2018

Lipids in Health and Disease, 2022
Background Lipid-lowering therapy is important, and the distribution of lipid levels and the incidence of hyperlipidemia may vary in different subgroups of the population.
Zhenhan Li, Guoqi Zhu, Guo Chen, Meiwen Luo, Xuebo Liu, Zhongpei Chen, J. Qian   +6 more
semanticscholar   +1 more source

Saroglitazar improved hepatic steatosis and fibrosis by modulating inflammatory cytokines and adiponectin in an animal model of non-alcoholic steatohepatitis

BMC Pharmacology and Toxicology, 2021
Background Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) have become significant global health concerns. In the present study, we aimed to investigate the effects of saroglitazar, a dual PPARα/γ agonist, fenofibrate ...
Rasoul Akbari, Tahereh Behdarvand, Reza Afarin, Hamid Yaghooti, Mohammad Taha Jalali, Narges Mohammadtaghvaei   +5 more
doaj   +1 more source

Capparis spinosa improves non-alcoholic steatohepatitis through down-regulating SREBP-1c and a PPARα-independent pathway in high-fat diet-fed rats

BMC Research Notes, 2022
Objective Non-alcoholic steatohepatitis (NASH) has become a global medical problem. Currently, there is no approved pharmacologic treatment for this condition.
Rasoul Akbari, Hamid Yaghooti, Mohammad Taha Jalali, Laya Sadat Khorsandi, Narges Mohammadtaghvaei   +4 more
doaj   +1 more source